Vaxart Accelerates Development of Ebola Tablet Vaccine

Vaxart to Present at the JMP Securities Life Sciences Private Company Conference on Friday, October 17, 2014

Vaxart’s Tablet Vaccine for H1N1 Influenza Generates Protective Immunity Equivalent to Injectable in Phase I Clinical Study

Vaxart to Present at the 15th Annual World Vaccine Congress in Brussels

Vaxart Appoints John Harland as Chief Financial Officer

Vaxart’s Oral H1N1 Influenza Vaccine Generates Protective Immunity

Vaxart Creates Effective Oral H7N9 Avian Influenza Vaccine in 20 Days

Vaxart’s Ground breaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans

Vaxart Begins First Oral Vaccine Clinical Trial

VAXART RAISES $12.5 MILLION SERIES B FINANCING